Equity Profile

VERA

Vera Therapeutics, Inc.

Health CareBiotechnology$3.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's market performance and acceptance of its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VERA Q2-2026 Earnings Preview

Context

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases. Operating in the health care sector, its work is crucial as it addresses unmet medical needs and aims to improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

In Q1-2026, Vera reported an EPS of -$1.69, which was significantly worse than the expected -$1.26, leading to a 1.95% decline in stock price the following day. The company has struggled to meet earnings expectations in recent quarters.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are cautious as Vera has consistently missed earnings estimates in recent quarters. Investors are looking for signs of improvement in both earnings and revenue.

Bull Case

If Vera can show a significant reduction in losses and positive revenue growth, it could signal a turnaround, attracting more investor interest.

Bear Case

Continued losses and failure to meet expectations could lead to further declines in stock price, as investor confidence wanes.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's history of missing EPS estimates, this figure will be crucial in assessing whether Vera is making progress in its financial recovery.

How has revenue changed compared to previous quarters?

Revenue growth is essential for evaluating the market acceptance of Vera's therapies and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Vera to narrow its losses significantly this quarter, as recent developments in their pipeline could lead to better-than-expected outcomes.

Supporting Evidence

Options are pricing a 41.6% move, indicating high uncertainty that may not align with the company's actual performance.

The historical trend shows that even with misses, the stock has occasionally reacted positively, suggesting potential for upside.

Key Risk

If EPS comes in below -$1.50, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether Vera can stabilize its financial situation and regain investor confidence.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$2.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±41.6%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating high uncertainty around the earnings report.

Options are pricing ±41.6% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

50.5%

Calls (14K)P/C Ratio: 0.02Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats expectations, history suggests a potential stock increase of around 3.5%, confirming a positive shift in the company's trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

If Vera misses again, history suggests a decline of about 2.15%, reflecting ongoing investor concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline and their expected impact on revenue.
2Management's commentary on cost management and plans to reduce losses.
3Details on market reception for existing products and any new partnerships.
4Guidance on future earnings expectations and strategic priorities.
5Insights into competitive landscape changes and how Vera plans to adapt.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's market performance and acceptance of its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VERA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are cautious as Vera has consistently missed earnings estimates in recent quarters. Investors are looking for signs of improvement in both earnings and revenue.

Bull Case

If Vera can show a significant reduction in losses and positive revenue growth, it could signal a turnaround, attracting more investor interest.

Bear Case

Continued losses and failure to meet expectations could lead to further declines in stock price, as investor confidence wanes.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's history of missing EPS estimates, this figure will be crucial in assessing whether Vera is making progress in its financial recovery.

How has revenue changed compared to previous quarters?

Revenue growth is essential for evaluating the market acceptance of Vera's therapies and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Vera to narrow its losses significantly this quarter, as recent developments in their pipeline could lead to better-than-expected outcomes.

Supporting Evidence

Options are pricing a 41.6% move, indicating high uncertainty that may not align with the company's actual performance.

The historical trend shows that even with misses, the stock has occasionally reacted positively, suggesting potential for upside.

Key Risk

If EPS comes in below -$1.50, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether Vera can stabilize its financial situation and regain investor confidence.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$2.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±41.6%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating high uncertainty around the earnings report.

Options are pricing ±41.6% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

50.5%

Calls (14K)P/C Ratio: 0.02Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats expectations, history suggests a potential stock increase of around 3.5%, confirming a positive shift in the company's trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

If Vera misses again, history suggests a decline of about 2.15%, reflecting ongoing investor concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline and their expected impact on revenue.
2Management's commentary on cost management and plans to reduce losses.
3Details on market reception for existing products and any new partnerships.
4Guidance on future earnings expectations and strategic priorities.
5Insights into competitive landscape changes and how Vera plans to adapt.